|
SLNO | Soleno Therapeutics Inc |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.32 |
| Leverage | 17.52% |
| Market Cap | $ 1.6B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -79.0m |
| Margin | -72.60% |
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of rare diseases. The company is headquartered in Redwood City, California.